Claims against Janssen Pharmaceuticals over the efficacy of the blood thinner Xarelto will be wrapped into Philadelphia’s existing mass tort that focuses on claims the drug led to excessive bleeding, under a court order issued Wednesday.
Philadelphia Court of Common Pleas Judge Arnold New issued a case management order transferring Mothena v. Janssen Research & Development to the Xarelto mass tort. The one-page order granted Janssen’s October petition asking the court to transfer the case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
